Intrapleural rituximab for the treatment of malignant pleural effusion due to B-cell lymphomas

Law, Man Fai; Yip, Sze Fai; Poon, Wai Lun; Chan, Hay Nun; Lai, Ho Kei; Ha, Chung Yin; Ng, Chi‐Fai; Yeung, Yiu Ming

doi:10.3109/10428194.2011.602769

Cited by 3 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This case report is in accordance with other reports [1][2][3][4][5] and shows that i.p. or intrapleural administration of rituximab seems to be safe routes, as no acute side effects have occurred.…”

Section: Dear Editorsupporting

confidence: 95%

See 1 more Smart Citation

Successful intraperitoneal rituximab treatment in a patient with therapy-resistant malignant ascites due to mantle cell lymphoma

Mörth

Hagberg

2015

Ann Hematol

View full text Add to dashboard Cite

Section: Dear Editorsupporting

confidence: 95%

“…or subcutaneously. There are only a few reports showing treatment responses with rituximab administration intrapleural [1][2][3] or intraperitoneal (i.p.) [4,5].…”

Section: Dear Editormentioning

confidence: 99%

Successful intraperitoneal rituximab treatment in a patient with therapy-resistant malignant ascites due to mantle cell lymphoma

Mörth

Hagberg

2015

Ann Hematol

View full text Add to dashboard Cite

“…Experience with intrapleural administration of rituximab is more extensive than experience with intrapericardial infusion. The drug has been administered to patients with resistant or recurrent disease and has been shown to be safe and effective in several trials [16,17]. This procedure was performed in our patient at a dose that has been described previously, i.e.…”

Section: Discussionmentioning

confidence: 99%

“…This antibody may also be administered locally, and this method is now being tested on a larger scale in the treatment of cutaneous B cell lymphomas [9]. There are also a few descriptions of intrathecal, intravitreal and intrapleural administration of rituximab [10,11,12,13,14,15,16,17]. However, we were unable to find, in the available literature, reports of intrapericardial administration of rituximab to patients in whom the heart serosa was involved.…”

Section: Introductionmentioning

confidence: 99%

Intrapericardial and Intrapleural Administration of Rituximab to a Patient with Marginal Zone Lymphoma

Boguradzki

Drozd-Sokołowska²,

Wieczorek³

et al. 2013

Acta Haematol

View full text Add to dashboard Cite

The addition of rituximab to standard chemotherapy has improved the results of the treatment of B cell non-Hodgkin's lymphomas. Under specific circumstances, it can be administered locally, as an alternative to systemic administration. We administered rituximab intrapericardially in an attempt to control pericardial effusion. We report the case of an 85-year-old woman, diagnosed with marginal zone lymphoma, who developed heart failure due to lymphomatous infiltration of the pericardium. We discuss in detail the possibility of intrapericardial treatment of such patients. The patient received rituximab intrapericardially at a dose of 100 mg in addition to systemic rituximab, cyclophosphamide, vincristine and prednisone immunochemotherapy. The treatment proved to be safe and effective. The patient has remained in good health for more than 3 years at the time of writing. Intrapericardial administration of rituximab may be a valuable therapeutic option for patients with lymphoma that involves the pericardium and heart.

show abstract

“…132,133 Intrapleural and intraperitoneal administration of rituximab for the treatment of recurrent malignant pleural effusions or abdominal ascites unresponsive to systemic therapy have been reported in individual cases with NHL. [134][135][136][137] The intracavity administration of rituximab seems to be effective in some cases with no significant side effects.…”

Section: Dovepressmentioning

confidence: 99%

The evaluation and optimal use of rituximab in lymphoid malignancies

Robak¹,

Robak²,

Smolewski³

2012

BLCTT

View full text Add to dashboard Cite

Rituximab is an IgG1, chimeric monoclonal antibody (mAb) containing murine light-and heavy-chain variable-region sequences and human constant-region sequences. Rituximab targets the CD20 molecule expressed on normal and malignant B-lymphocytes. At present, rituximab is the most important mAb of clinical value in patients with B-cell lymphoid malignancies. Since approval in 1997, rituximab has become widely used in chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), and diffused large B-cell lymphoma (DLBCL) when combined with chemotherapy. Currently, rituximab is commonly combined with first-line chemotherapy for FL and should be offered as maintenance therapy to all appropriate patients with this disease. Randomized Phase III trials demonstrated the superiority of rituximab added to CHOP chemotherapy against CHOP chemotherapy alone in patients with DLBCL. Rituximab alone has limited activity in MCL but can be used in MCL in combination with chemotherapy, despite the benefits not being as impressive as when used against other lymphoma entities. In addition, for the less frequent B-cell lymphomas, small series show considerable activity for most of these entities. Fludarabine and rituximab combination therapies in CLL yielded promising results in several studies. Two large Phase III randomized trials demonstrated the superiority of chemoimmunotherapy with rituximab compared with chemotherapy alone in previously untreated and refractory/relapsed patients with CLL. Therefore, it can be concluded that rituximab, with only few exceptions, can generally be accepted as a standard component of anti B-cell non-Hodgkin's lymphoma therapies. In this review, the pharmacology, mode of action, pharmacokinetics, and current place in the therapy of B-cell lymphoid malignancies of rituximab are presented. In addition, an overview of studies conducted to date and optimal use of this drug, including timing and doses, is presented.

show abstract

Intrapleural rituximab for the treatment of malignant pleural effusion due to B-cell lymphomas

Cited by 3 publications

References 11 publications

Successful intraperitoneal rituximab treatment in a patient with therapy-resistant malignant ascites due to mantle cell lymphoma

Successful intraperitoneal rituximab treatment in a patient with therapy-resistant malignant ascites due to mantle cell lymphoma

Intrapericardial and Intrapleural Administration of Rituximab to a Patient with Marginal Zone Lymphoma

The evaluation and optimal use of rituximab in lymphoid malignancies

Contact Info

Product

Resources

About